El-Kassar N, Hetet G, Brière J, Grandchamp B
INSERM U409, Association Claude Bernard, and Service d'hématologie clinique, Faculté de Medéecine Bichat, Paris, France.
Leuk Lymphoma. 1998 Jun;30(1-2):181-8. doi: 10.3109/10428199809050941.
Essential thrombocythemia (ET) is a myeloproliferative disorder, characterized by sustained thrombocytosis. Diagnosis requires the elimination of all known causes of thrombocytosis. ET is believed to be a clonal disorder, and we investigated the frequency of a clonal hematopoiesis in this disease with the aim of using this as a positive diagnostic criterion. However, a non-random inactivation pattern can be encountered in normal females which mimics clonal hematopoiesis. In addition, the percentage of normal females with skewed lyonization seems higher using techniques based on the difference in DNA methylation, compared to G6PD enzyme polymorphism. Recently, new techniques based on transcript analysis have been developed. We report here the results of clonality studies of hematopoiesis in 53 ET patients using two different techniques based on DNA and RNA polymorphisms, and T-lymphocytes as a control tissue of lyonization. The majority of ET patients showed monoclonal hematopoiesis in the presence of polyclonality of T-lymphocytes. Because all ET patients did not show the same clonal pattern of hematopoiesis, we searched for inappropriate secretion of thrombopoietin (TPO) in patients with polyclonal disease. This assay was performed in 48 patients, of whom 9 showed polyclonal hematopoiesis and 27 monoclonal hematopoiesis. We found no difference in TPO levels between ET patients and normal controls, nor between patients with polyclonal hematopoiesis and those with monoclonal hematopoiesis. Our results confirm the high frequency of monoclonal hematopoiesis in ET, the usefulness of RNA markers, and the possibility of using T-lymphocytes as a control tissue for X-chromosome inactivation patterns. On the other hand, TPO levels are not decreased even in ET patients with high platelet counts, suggesting an increased production or decreased clearance of TPO in this disease.
原发性血小板增多症(ET)是一种骨髓增殖性疾病,其特征为持续性血小板增多。诊断需要排除所有已知的血小板增多原因。ET被认为是一种克隆性疾病,我们研究了该疾病中克隆性造血的频率,旨在将其用作阳性诊断标准。然而,正常女性可能会出现非随机失活模式,这与克隆性造血相似。此外,与基于葡萄糖-6-磷酸脱氢酶(G6PD)酶多态性的技术相比,使用基于DNA甲基化差异的技术时,具有偏态莱昂化的正常女性比例似乎更高。最近,基于转录分析的新技术已经开发出来。我们在此报告了使用基于DNA和RNA多态性的两种不同技术以及T淋巴细胞作为莱昂化对照组织,对53例ET患者进行造血克隆性研究的结果。大多数ET患者在T淋巴细胞多克隆性的情况下表现出单克隆造血。由于并非所有ET患者都表现出相同的造血克隆模式,我们在多克隆疾病患者中寻找血小板生成素(TPO)的不适当分泌情况。对48例患者进行了该检测,其中9例表现为多克隆造血,27例表现为单克隆造血。我们发现ET患者与正常对照之间、多克隆造血患者与单克隆造血患者之间的TPO水平没有差异。我们的结果证实了ET中单克隆造血的高频率、RNA标志物的有用性以及使用T淋巴细胞作为X染色体失活模式对照组织的可能性。另一方面,即使是血小板计数高的ET患者,TPO水平也没有降低,这表明该疾病中TPO的产生增加或清除减少。